2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - Hall C
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Biological Processes, Pathogenesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

775 Targeting immunosuppressive atypical memory B cells enhances CAR T cell efficacy in acute myeloid leukemia

Adrian Gottschlich, MD, Vladyslav Kavaka, MD2, Thomas Alexander Janert3, Veronika Igl, MD4, Lisa Rohrbacher, PhD5, Ruth Grünmeier, MD6, Christian Rausch, MD7, Sayantan Nandi, PhD8, Emanuele Carlini, PhD9, Franziska Brauneck, MD10, Moritz Kruppa11, Stephanie Frenz-Wiessner, MD12, Isabel Huelya Goek, MSc13, Moritz Thomas, PhD14, Niklas Kehl, MD15, Ruben Brabenec16, Daria Briukhovetska, PhD17, Arman Oner, MD18, Jakob Harwood19, Wendy den Hartog20, Marcel Trefny, PhD21, Philipp Penovici22, Rasmus David Müller23, Lilli Ye Ballheimer24, Christina Tsiverioti25, Gordon Victor Hoffmann26, Sophia Stock, MD27, Philipp Xi Müller28, Walter Fiedler, MD29, Michael Rade, PhD30, Markus Kreuz31, Anand Bhagwat, MD32, Dominik Steiner, MD33, Johannes Tobias Thiel, MD34, Henrik Lauer, MD35, Christoph Klein V, MD36, Carsten Marr, PhD37, Stefan Endres38, Martina Rudelius, MD39, Mirco Julian Friedrich, MD, PhD40, Tobias Herold, MD41, Karsten Spiekermann, MD42, Kristin Reiche, PhD43, Maximilian Merz, MD44, Saar Gill, MD, PhD45, Marion Subklewe I, MD46, Michael Von Bergwelt, MD47, Sebastian Kobold, MD48
1 Bavarian Cancer Research Center (BZKF), Munich, Germany, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Mass General Brigham, Boston, Massachusetts, United States, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Harvard Medical School, Boston, Massachusetts, United States, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
2 Department of Hand, Plastic, Reconstructive and Burn Surgery, BG Unfallklinik Tuebingen, Eberhard Karl University Tuebingen, Tuebingen, Germany, Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany
3 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
4 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
5 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany
6 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
7 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
8 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
9 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
10 Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Mildred Scheel Cancer Career Center, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf Hamburg, Hamburg, Germany
11 Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf,, Hamburg, Germany
12 Department of Molecular, Cell and Developmental Biology, University of California Los Angeles, Los Angeles, United States, Department of Pediatrics, Dr. von Hauner Children’s Hospital, LMU University Hospital, LMU Munich, Munich, Germany, German Center for Child and Adolescent Health, Partner Site Munich, Munich, Germany
13 Department of Pediatrics, Dr. von Hauner Children’s Hospital, LMU University Hospital, LMU Munich, Munich, Germany
14 Institute of AI for Health, Helmholtz Zentrum München - German Research Center for Environmental Health Neuherberg, Neuherberg, Germany, School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany
15 Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany
16 Institute of AI for Health, Helmholtz Zentrum München - German Research Center for Environmental Health Neuherberg, Neuherberg, Germany, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
17 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
18 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
19 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
20 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
21 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
22 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
23 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
24 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
25 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
26 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
27 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
28 Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
29 Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
30 Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany
31 Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany
32 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia,, Philadelphia, Pennsylvania, United States
33 Department of Hand, Plastic, Reconstructive and Burn Surgery, BG Unfallklinik Tuebingen, Eberhard Karl University Tuebingen, Tuebingen, Germany
34 Department of Hand, Plastic, Reconstructive and Burn Surgery, BG Unfallklinik Tuebingen, Eberhard Karl University Tuebingen, Tuebingen, Germany
35 Department of Hand, Plastic, Reconstructive and Burn Surgery, BG Unfallklinik Tuebingen, Eberhard Karl University Tuebingen, Tuebingen, Germany
36 Department of Pediatrics, Dr. von Hauner Children’s Hospital, LMU University Hospital, LMU Munich, Munich, Germany, Gene Center, LMU Munich, Munich, Germany, German Center for Child and Adolescent Health, Partner Site Munich, Munich, Germany
37 Institute of AI for Health, Helmholtz Zentrum München - German Research Center for Environmental Health Neuherberg, Neuherberg, Germany
38 Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München - German Research Center for Environmental Health Neuherberg, Neuherberg, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
39 Institute of Pathology, Ludwig Maximilian University Munich, Munich, Germany
40 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany
41 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
42 Bavarian Cancer Research Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
43 Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany, Institute for Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany
44 Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany, Myeloma and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States
45 Center for Cell Therapy and Transplant, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
46 Bavarian Cancer Research Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany
47 Bavarian Cancer Research Center (BZKF), Munich, Germany, Department of Medicine III, LMU University Hospital, Comprehensive Cancer Center München, Munich, Germany, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
48 Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München - German Research Center for Environmental Health Neuherberg, Neuherberg, Germany, German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany, German Center for Lung Research (DZL), partner site Munich, Munich, Germany, Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

T cell-engaging immunotherapies have achieved remarkable success in B cell malignancies (Majzner et al., Nat. Med. 2019), yet their efficacy in acute myeloid leukemia (AML) has fallen short of these high expectations (Cummins & Gill, Haematologica, 2019). Failure has been linked to a profoundly immunosuppressive bone marrow microenvironment that impairs T cell survival and function (Haubner et al., 2025, Blood). While myeloid cell-driven immune suppression has been studied extensively, B cells are only beginning to emerge as central contributors (Lasry et al., Nat. Cancer, 2023). The exact mechanisms underlying their reprogramming and B cell-driven immune inhibition within the AML microenvironment remain elusive. Targeting the cellular drivers of this immunosuppression could enable more effective cellular therapies.

To map the B cell landscape of AML, we performed integrative single-cell RNA (scRNA-Seq) and B cell receptor sequencing analysis across two independent AML cohorts (>200,000 total sequenced cells, n=52 patients, mean blast percentage ≈38%), including both first diagnosis and relapsed and refractory AML samples. This revealed a consistent and selective enrichment of clonally expanded memory B cells in the AML-affected bone marrow compared to healthy tissue, marked by high expression of atypical-lineage genes (FCRL3/4/5; Batyp), an anti-apoptotic signature dominated by BCL2, elevated adaptive inhibitory molecules such as PD-L1, PD-L2, BTLA and IL-10, as well as the innate immune sensors TLR9 and TLR10. A high Batyp transcriptional signature was associated with inferior overall survival in the TCGA-AML cohort (n=173).

Flow cytometry across two AML cohorts (n=49) confirmed enrichment of CD27-IgD- Batyp highly positive for PD-L1 and BTLA. Functionally, AML-derived Batyp potently suppressed T cell proliferation relative to naïve B cells or healthy-donor counterparts, an effect partially reversed by PD-1 checkpoint inhibition. Co-culture of B cells with primary AML blasts and AML-engrafted iPSC-derived bone marrow organoids, but not with acute lymphoblastic leukemia cells, drove expansion of this immunosuppressive subset with induction of BCL2, T-bet, PD-L1 and PD-L2, identifying AML blasts as direct drivers of Batyp reprogramming.

Strikingly, Batyp were highly enriched in patients failing CAR T cell therapy. ScRNA-Seq analysis of AML patients treated with CD123 CAR T cells (NCT03766126) and of multiple myeloma patients treated with BCMA CAR T cells showed selective accumulation of Batyp in non-responders, linking this cell population to therapeutic resistance across malignancies and CAR T cell products.

To overcome this resistance, we performed differential gene expression analysis to identify novel surface antigens shared between Batyp and AML blasts. We identified CD180, a TLR-related molecule highly and selectively expressed on both populations, with a myeloid- and B cell-restricted off-tumor profile and minimal expression on healthy hematopoietic stem and progenitor cells (HSPC). Integrated bulk sequencing analyses spanning eight cohorts and >2,500 patients confirmed high CD180 expression, enriched in core-binding-factor as well as NPM1-, FLT3-, and RAS-mutated AML. High CD180 expression predicted inferior survival independent of genetics, whereas established AML and B cell antigens (CD33, CLL-1, CD19, CD20 and CD22) did not.

We generated second generation CD180-directed CAR T cells that lysed AML cell lines and primary blasts with potency comparable to CD33 CAR T cells, while completely sparing healthy HSPC. CD180 CAR T cells depleted B cells and showed superior activation as measured by IFNγ release. In vivo, they achieved complete leukemia clearance across multiple cell-line and two patient-derived xenograft models. Notably, in B cell-humanized AML models, CD180 CAR T cells outperformed CD33 CAR T cells, with enhanced expansion and activation driving near-complete tumor eradication.

Collectively, our findings establish Batyp as a previously unrecognized, targetable immunosuppressive population induced by leukemic blasts that predicts CAR T cell resistance in AML and multiple myeloma. By exploiting CD180 as a shared antigen, CD180-directed CAR T cells eliminate both malignant blasts and B cells, turning B cell engagement into a co-stimulatory advantage and establishing B cell co-targeting as a generalizable principle to overcome immune resistance and enhance CAR T cell efficacy in AML and beyond.

Adrian Gottschlich, MD: Ipsen - Current holder of stock options in a privately-held company; NovoNordisk - Current holder of stock options in a privately-held company; Plectonic - Research Funding; Kite Gilead - Consultancy (Includes expert testimony)